Tissue Microarrays, A Revolution in Pathology Research
Abstract
A long-lasting problem in the analysis of tissue samples is the time-consuming and repetitive process of histologic preparation and pathologic review of tissue sections. These two critical factors, innate nonuniformity in preparation and subjectivity of analysis, therefore limit the scientific and statistical thoroughness of tissue based studies. Employing tissue microarray (TMA) technique provides a potential solution to each of these problems. This review discusses the methods of creating tissue microarrays, the advantages and disadvantages of the technology, analysis methods, and recent TMA applications.Battifora H. The multitumor (sausage) tissue block: novel meth- od for immunohistochemical antibody testing. Lab Invest. 1986 Aug;55(2):244-8.
Wan WH, Fortuna MB, Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods. 1987 Oct 23;103(1):121-9.
Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997 Aug;15(8):2894-904.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998 Jul;4(7):844-7.
Giltnane JM, Rimm DL. Technology insight: Identification of bio- markers with tissue microarray technology. Nat Clin Pract Oncol. 2004 Dec;1(2):104-11.
DeVita VT, Hellman S, Rosenberg SA. Cancer, principles & practice of oncology / edited by Vincent T. DeVita, Jr., Samuel Hellman, Steven A. Rosenberg. 7th ed ed: Lippincott Williams & Wilkins; 2005.
Taeb J, Asgari M, Abolhasani M, Farajollahi MM, Madjd Z. Expres- sion of prostate stem cell antigen (PSCA) in prostate cancer: A tissue microarray study of Iranian patients. Pathol Res Pract. 2013 Oct 11.
Mohsenzadegan M, Madjd Z, Asgari M, Abolhasani M, Shekarabi M, Taeb J, et al. Reduced expression of NGEP is associated with high- grade prostate cancers: a tissue microarray analysis. Cancer Immunol Immunother. 2013 Oct;62(10):1609-18.
Sotoudeh K, Hashemi F, Madjd Z, Sadeghipour A, Molanaei S, Ka- lantary E. The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Diagn Pathol. 2012;7:57.
Mehrazma M, Madjd Z, Kalantari E, Panahi M, Hendi A, Sharifta- brizi A. Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray. Fetal Pediatr Pathol. 2013 Jun;32(3):192-204.
Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, et al. Upregulation of MICA on high-grade invasive operable breast carci- noma. Cancer Immun. 2007;7:17.
Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resourc- es. Cancer J. 2001 Jan-Feb;7(1):24-31.
Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E. Amplifi- cation of tissue by construction of tissue microarrays. Exp Mol Pathol. 2001 Jun;70(3):255-64.
Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-through- put in situ studies. J Pathol. 2001 Sep;195(1):72-9.
Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000 Dec;80(12):1943-9.
Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001 Dec;159(6):2249-56.
Nocito A, Bubendorf L, Tinner EM, Suess K, Wagner U, Forster T, et al. Microarrays of bladder cancer tissue are highly represen- tative of proliferation index and histological grade. J Pathol. 2001 Jul;194(3):349-57.
Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY. Characterization of matriptase expression in normal human tissues. J Histochem Cytochem. 2003 Aug;51(8):1017-25.
Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest. 2001 Oct;81(10):1331-8.
Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cor- nelison R, et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 2002 Mar 1;62(5):1256-60.
Jubb AM, Landon TH, Burwick J, Pham TQ, Frantz GD, Cairns B, et al. Quantitative analysis of colorectal tissue microarrays by immuno- fluorescence and in situ hybridization. J Pathol. 2003 Aug;200(5):577- 88.
Li H, Sun Y, Kong QY, Zhang KL, Wang XW, Chen XY, et al. Com- bination of nucleic acid and protein isolation with tissue array construc- tion: using defined histologic regions in single frozen tissue blocks for multiple research purposes. Int J Mol Med. 2003 Sep;12(3):299-304.
McCarty KS, Jr., Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986 Aug;46(8 Suppl):4244s-8s.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and pre- dictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998 Feb;11(2):155-68.
McCarty KS, Jr., Miller LS, Cox EB, Konrath J, McCarty KS, Sr. Estrogen receptor analyses. Correlation of biochemical and immuno- histochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985 Aug;109(8):716-21.
Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002 Apr 3;287(13):1662-70.
Parker RL, Huntsman DG, Lesack DW, Cupples JB, Grant DR, Ak- bari M, et al. Assessment of interlaboratory variation in the immuno- histochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002 May;117(5):723-8.
De la Taille A, Viellefond A, Berger N, Boucher E, De Fromont M, Fondimare A, et al. Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays. Hum Pathol. 2003 May;34(5):444-9.
Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Herme- link HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol. 2002 Nov;198(3):292-9.
Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, et al. Cyclin E overexpression and amplification in human tumours. J Pathol. 2003 Jul;200(3):375-82.
Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, et al. Survey of gene amplifications during prostate cancer progres- sion by high-throughout fluorescence in situ hybridization on tissue mi- croarrays. Cancer Res. 1999 Feb 15;59(4):803-6.
Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML. E- cadherin expression in prostate cancer: a broad survey using high-den- sity tissue microarray technology. Hum Pathol. 2001 Jul;32(7):690-7.
Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Schole- field JH, et al. Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J Surg Oncol. 2005 Jul 19;3:47.
Watson NF, Durrant LG, Scholefield JH, Madjd Z, Scrimgeour D, Spendlove I, et al. Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients. World J Gas- troenterol. 2006 Oct 21;12(39):6299-304.
Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, Spend- love I. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal can- cer patients. Cancer Immunol Immunother. 2006 Aug;55(8):973-80.
Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scho- lefield JH, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression cor- relates with a poor prognosis. Int J Cancer. 2006 Jan 1;118(1):6-10.
Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer. 2006 Mar 15;118(6):1445-52.
Madjd Z, Durrant LG, Pinder SE, Ellis IO, Ronan J, Lewis S, et al. Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)? Cancer Immunol Immunother. 2005 Feb;54(2):149-56.
Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res. 2004 Apr 15;10(8):2797-803.
Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M. CD44+ cancer cells express higher levels of the anti- apoptotic protein Bcl-2 in breast tumours. Cancer Immun. 2009;9:4.
Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG. High expression of Lewis y/b antigens is associated with decreased sur- vival in lymph node negative breast carcinomas. Breast Cancer Res. 2005;7(5):R780-7.
Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG. Loss of CD59 expression in breast tumours correlates with poor sur- vival. J Pathol. 2003 Aug;200(5):633-9.
Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer. 2005 Nov 1;117(2):248-55.
Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, Spendlove I. The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer. 2007 Mar;14(1):73-80.
Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, et al. Cytogenetic alterations and cytokeratin expression pat- terns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest. 2002 Nov;82(11):1525-33.
Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, et al. Immu- noprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 2003 Mar;442(3):271-7.
Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, et al. Tissue microarrays are an effective quality assurance tool for diag- nostic immunohistochemistry. Mod Pathol. 2002 Dec;15(12):1374-80.
Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K, Gilks CB, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 2002 Nov;161(5):1557-65.
Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8.
Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 2003 Mar 1;63(5):1101-5.
Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, et al. Analysis of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003 Jun 1;63(11):2742-6.
- Madjd Z, Akbari ME, Zarnani AH, Khayamzadeh M, Kalantari E, Mojtabavi N. Expression of EMSY, a Novel BRCA2-link Protein, is Associated with Lymph Node Metastasis and Increased Tumor Size in Breast Carcinomas.
- Roudi R, Madjd Z, Korourian A, Mehrazma M, Molanae S, Sa- bet MN, et al. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer.
- Keymoosi H, Gheytanchi E, Asgari M, Shariftabrizi A, Madjd Z. ALDH1 in Combination with CD44 as Putative Cancer Stem Cell Markers are Correlated with Poor Prognosis in Urothelial Carcinoma of the Urinary Bladder.
- Larijani L, Madjd Z, Samadikuchaksaraei A, Younespour S, Zham H, Rakhshan A, et al. Methylation of O6-Methyl Guanine Methyltrans- ferase Gene Promoter in Meningiomas-Comparison between Tumor Grades I, II, and III.
- Sabet MN, Rakhshan A, Erfani E, Madjd Z. Co-Expression of Puta- tive Cancer Stem Cell Markers, CD133 and Nestin, in Skin Tumors.
| Files | ||
| Issue | Vol 6 No 1 (2014) | |
| Section | Reviews | |
| Keywords | ||
| #No Keywords# | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
